Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s12975-013-0281-2
Title: | Therapeutic Antibodies in Stroke | Authors: | Yu, C.Y Ng, G Liao, P |
Keywords: | adalimumab alpha amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid CD18 antibody CD18 antigen endothelial leukocyte adhesion molecule 1 endothelial leukocyte adhesion molecule 1 antibody enlimomab Fas ligand glutamate receptor antagonist infliximab intercellular adhesion molecule 1 intercellular adhesion molecule 1 antibody interleukin 8 interleukin 8 antibody L selectin l selectin antibody monoclonal antibody myelin associated glycoprotein n methyl dextro aspartic acid receptor neutralizing antibody Nogo 66 receptor Nogo A antibody oligodendrocyte myelin glycoprotein PADGEM protein protein antibody protein Nogo A recombinant plasminogen activator tissue plasminogen activator unclassified drug active immunization acute kidney failure anaphylaxis aseptic meningitis blood brain barrier brain damage brain edema brain hemorrhage brain ischemia cell infiltration cerebrovascular accident Crohn disease deterioration diarrhea dyspnea fatigue fever headache heart arrest heart infarction heart palpitation hoarseness human immunotherapy leukocyte function lung edema lung embolism malaise meningitis middle cerebral artery occlusion nausea nerve cell plasticity passive immunization pneumonia priority journal protein subunit review rheumatoid arthritis side effect spinal cord injury stroke related deterioration tissue injury treatment failure vein thrombosis Antibody Immunotherapy Stroke Animals Antibodies Biomedical Research Cell Adhesion Molecules Cytokines Humans Immunologic Factors Immunotherapy Myelin Proteins Neuroprotective Agents Stroke |
Issue Date: | 2013 | Citation: | Yu, C.Y, Ng, G, Liao, P (2013). Therapeutic Antibodies in Stroke. Translational Stroke Research 4 (5) : 477-483. ScholarBank@NUS Repository. https://doi.org/10.1007/s12975-013-0281-2 | Rights: | Attribution 4.0 International | Abstract: | Immunotherapy represents an active area of biomedical research to treat cancer, autoimmune diseases, and neurodegenerative disorders. In stroke, recanalization therapy is effective in reducing brain tissue damage after acute ischemic stroke. However, the narrow time window restricts its application for the majority of stroke patients. There is an urgent need to develop adjuvant therapies such as immunotherapy, stem cell replacement, and neuroprotective drugs. A number of molecules have been targeted for immunotherapy in stroke management, including myelin-associated proteins and their receptors, N-methyl-d-aspartic acid receptors, cytokines, and cell adhesion molecules. Both active vaccination and passive antibodies were tested in animal models of acute ischemic stroke. However, the mechanisms underlying the efficacy of immunotherapy are different for each target protein. Blocking myelin-associated proteins may enhance neuroplasticity, whereas blocking adhesion molecules may yield neuroprotection by suppressing the immune response after stroke. Although results from animal studies are encouraging, clinical trials using therapeutic antibodies failed to improve stroke outcome due to severe side effects. It remains a challenge to generate specific therapeutic antibodies with minimal side effects on other organs and systems. © 2013 The Author(s). | Source Title: | Translational Stroke Research | URI: | https://scholarbank.nus.edu.sg/handle/10635/181806 | ISSN: | 18684483 | DOI: | 10.1007/s12975-013-0281-2 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1007_s12975-013-0281-2.pdf | 173.08 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License